nLite360®

Access to high-quality, affordable medical devices is a global problem, but it is particularly severe in indigenous communities. In these communities, there is often limited access to quality healthcare, which exacerbates the effects of illnesses and diseases. The lack of access to high-quality medical devices only compounds these issues, resulting in prolonged illness, increased mortality rates, and a cycle of poverty.

In the case of newborn jaundice, it is a problem that affects millions of babies worldwide, but it is especially prevalent in indigenous communities where healthcare access is limited. The high cost and limited accessibility of effective phototherapy devices mean that many newborns do not receive the necessary treatment, leading to severe jaundice, brain damage, and death.

The WHO reports that 45% of severe neonatal jaundice cases in developing countries result in mortality or lifetime disabilities. Globally 42million babies suffer from severe jaundice, with a significant proportion of those babies born in indigenous communities. Additionally, many of these communities lack access to hospitals or clinics with the necessary equipment to treat severe jaundice, making the problem even more acute.

The lack of access to quality healthcare and medical devices is a systemic problem that affects indigenous communities around the world. The Heamac Healthcare team is committed to addressing this problem by developing affordable and accessible medical devices that can be used in a range of healthcare settings. By doing so, we hope to help reduce mortality rates and improve the quality of life for those living in indigenous communities and beyond.

Certainly! Our solution is specifically designed to address the needs of indigenous communities, who often have limited access to quality healthcare services. In these communities, newborn jaundice can be a significant health issue that is often neglected due to a lack of resources and trained medical professionals. Our device offers a simple and cost-effective solution that can be used in low-resource settings, making it an ideal choice for indigenous communities.
Our solution is a portable, affordable, and effective phototherapy device for the treatment of severe jaundice in newborns. The device uses blue LED lights to emit the exact wavelength of light required to break down excess bilirubin in the blood. The device is designed to be easy to use, transport, and maintain, making it an ideal solution for rural and remote areas where traditional phototherapy devices are not accessible.
The device is equipped with sensors that monitor the intensity of light emitted, ensuring that the newborn receives the optimal amount of light required for effective treatment. The device also has a built-in alarm system that alerts hospital staff if there are any issues with the device or if the treatment is interrupted for any reason.
Our phototherapy device is designed to be affordable and accessible to healthcare facilities in low- and middle-income countries, particularly in indigenous communities where there is a significant burden of severe neonatal jaundice. Our solution addresses the problem of ineffective and inaccessible phototherapy devices, which are currently only available in high-end clinical settings.
By providing an affordable and portable solution, we aim to prevent the need for blood transfusions and reduce the mortality and disability rates associated with severe neonatal jaundice. Our solution not only provides a life-saving treatment option but also helps to create employment opportunities and improve the overall healthcare system in rural and remote areas.
Implementing our device in Indigenous communities can not only help to save the lives of newborns but also generate employment opportunities for community members. As many Indigenous communities face high rates of unemployment and poverty, this can provide much-needed economic development.
Moreover, our device aligns with the Truth and Reconciliation Commission of Canada's Call to Action #22, which calls for increased health resources for Indigenous communities. Our solution can contribute to closing the health gap and ensuring equitable access to healthcare for Indigenous peoples.
In the United States, Indigenous infants also face higher rates of neonatal jaundice than non-Indigenous infants, with rates ranging from 11.7% to 23.7% compared to 5.9% to 13.5%. The implementation of our device can provide a cost-effective and accessible solution for Indigenous communities. Overall, our solution for severe neonatal jaundice can have a significant impact on Indigenous communities, contributing to improved health outcomes, economic development, and closing the health gap.

The target population for our solution is newborn babies in rural areas who are at risk of developing severe jaundice. This includes Indigenous communities in Canada and United Stares who often face healthcare disparities and lack access to proper medical care. Currently, these communities are underserved due to a lack of medical facilities and resources, which often leads to inadequate treatment for babies with jaundice.

Currently, the only option for these families is to travel long distances to a district or town hospital for treatment, which is often not feasible due to the cost, time, and transportation barriers. This often leads to delayed treatment and poor outcomes for the babies, including the need for blood transfusions and even death.

Our solution directly addresses the needs of these communities by providing a portable and solar-powered neonatal phototherapy device that can be deployed by trained local clinical workers in rural areas. This eliminates the need for mothers to travel long distances to access medical care, which can be costly and time-consuming. The device also provides effective treatment for moderate-risk babies at home, allowing mothers to care for their babies while receiving treatment.

Furthermore, our solution creates employment opportunities for ASHA workers in rural areas, providing a boost to the local economy. This incentivizes workers to provide proper treatment and care for newborns, leading to better outcomes and reduced rates of neonatal deaths. By addressing the issue of severe jaundice in rural areas, we aim to improve the health and well-being of Indigenous communities and other underserved populations.

In terms of impact, our solution has the potential to save millions of newborns from critical jaundice globally, including 60 million babies in India alone. By discharging babies 50% earlier than traditional treatment methods, we can reduce the need for blood transfusions and prevent neonatal deaths. This not only improves the health outcomes for newborns but also reduces the burden on healthcare systems and resources.

In summary, our solution serves the target population of newborns in rural areas, including Indigenous communities in Canada and United Stares. By providing a portable and effective treatment for severe jaundice, we aim to improve health outcomes, create employment opportunities, and reduce neonatal deaths.

Our solution, nLite 360®, benefits Indigenous communities in US, Canada and India and Other developing countries,  that are completely disconnected from basic urban areas or cities, making healthcare facilities a luxury that they cannot afford. These communities face many healthcare problems that are not addressed, and even basic vaccination services are not accessible to them. Jaundice is a major challenge in these communities, and it requires high-end equipment that is not designed to work in such resource-constrained settings. During our one-year clinical immersion in rural and tribal hamlets, we realized that many donated devices were dumped aside due to the lack of expertise and resources required to operate and maintain them.

To understand the facilities, culture, and community, we engaged with the Indigenous population to develop a technology customized for their needs, including various geographical conditions, cultural differences, and resource constraints. Our solution is nLite 360®, a convertible phototherapy with a modular design that works on renewable energies, is battery-backed, and charged through solar power, wind energy, or any other kind of energy. It is a medical device and an electronic equipment that complies with all the regulations and safety standards, including electrical safety, medical device safety, and bio-compatible tests.

Our technology is designed to treat newborns suffering from jaundice at their mother's side in resource-constrained settings, where healthcare facilities are limited. The device is portable and can be taken to remote areas, providing the best care possible in challenging areas. This technology will benefit Indigenous communities by providing access to high-quality healthcare services that were previously unavailable due to the limitations of existing equipment. It will save newborns' lives by preventing them from needing blood transfusions and reducing the number of neonatal deaths.

As we develop our solution, we have engaged with the Indigenous population to understand their needs and challenges. Our solution is designed to be user-friendly, and we have trained the local clinical workers to operate and maintain the device. By generating employment opportunities for rural people, our technology will provide better employability for the Indigenous population while generating revenue for the primary healthcare centers, which can be used to improve the facilities in the rural healthcare system.

In conclusion, nLite 360® is a revolutionary technology that directly benefits and is located within the Indigenous communities in North America. It addresses the unique challenges faced by these communities, such as lack of access to healthcare services, inadequate equipment, and resource constraints. Our solution will improve the quality of life for Indigenous communities and save newborns' lives by providing access to high-quality healthcare services.

At Heamac Healthcare, we understand the gravity of the global problem of inadequate access to maternal and child healthcare. This problem is even more severe in indigenous communities where people face significant challenges in accessing basic healthcare services. 

the founder of Heamac Healthcare, was deeply moved to dedicate himself to work in the field of newborn care when he witnessed his own daughter struggling with jaundice and was being treated in the NICU. Being born and raised in an indigenous community where basic needs like education and healthcare were scarce, he had to work hard to secure scholarships and move to different provinces for better opportunities. His personal experience and understanding of the struggles and unmet needs of his community inspired him to give back by developing solutions in maternal and child health. With over a decade of experience in developing medical devices,

As a team, we have over a decade of experience in developing maternal and child healthcare medical devices, and we have brought together highly skilled individuals to support our vision. Our team includes experienced professionals like Akitha Kolloju, our CTO and Co-founder, who has a background in Biomedical Engineering and has experience in developing biomedical products like Myoelectric arm for half-limbed amputees and Non-invasive haemoglobin monitoring system for detecting Anaemia in adolescent girls and pregnant women.

Additionally, Karthikeyan Harikesavan, our Senior head of Electronics, has over 13 years of experience in Electronics circuit Design (Analog and Digital), Sensor's integration, EMI/EMC (CISPR 11), Embedded software(C), Verification, Validation, Regulatory (13485), Risk Management (14975- FMEA, FTA). He specializes in EMI/EMC (CISPR 11), ISO 13485:2003, MDD, and International Regulatory Compliance for Medical Devices.

We understand that understanding the needs of the communities we serve is crucial to our success. As a team, we are engaging these communities through various means such as conducting surveys, focus groups, and community outreach programs. We have also established partnerships with local organizations that work with these communities to gain insight into their challenges and unmet needs. These inputs are crucial in guiding the design and implementation of our solutions meaningfully.

At Heamac Healthcare, we are committed to ensuring that the communities we serve are active participants in the development of our solutions. We have an ongoing dialogue with these communities, and we are continually seeking feedback to improve our solutions. By involving the communities we serve, we can design and deliver solutions that meet their unique needs, ideas, and agendas.

In summary, as a team, we have the technical expertise, experience, and personal connection to the communities we serve to design and deliver maternal and child healthcare solutions that meet their unique needs. We understand the importance of engaging these communities and involving them in the design and implementation of our solutions, and we are committed to ensuring that our solutions are guided by their input, ideas, and agenda.

As the founder of Heamac Healthcare, I am applying to MIT Solve because we see it as a platform that can help us overcome various financial, technical, legal, cultural, and market barriers that we face. In particular, we hope that Solve can connect us with relevant stakeholders and provide us with strategic networking opportunities. In the healthcare industry, networking and publicity are crucial, and word-of-mouth recommendations and connections with organizations are essential to our success.

Our focus is on developing solutions for maternal and child healthcare, with a particular emphasis on addressing jaundice in newborns. This is a global problem, but it is especially severe in indigenous communities, where access to healthcare and resources is limited. In India, we have established connections with various national organizations, hospitals, and educational institutions, which has helped us in designing and reaching more customers, including local manufacturers. We believe that Solve can provide us with an accelerating platform to push us to the next level of scalability, particularly as we seek to expand into global markets.

In addition to India and Canada, we are interested in scaling our business into other countries where similar problems exist, such as the Middle East, Africa, Europe, and the USA. We want to collaborate with healthcare and educational institutions to connect with highly expert professors and students, which will help us establish our company in those markets. We are particularly interested in the nine-month program offered by Solve, which will allow us to interact with interdisciplinary teams and gain a wider perspective on existing markets and transitions. We hope to receive leadership and coaching as well as strategic advice that will help us overcome the challenges we face in expanding our company globally.

In conclusion, we believe that Solve can provide us with the necessary connections, resources, and support to overcome the barriers we face in growing our company and expanding our solutions globally. We are excited to be part of the Solver team and to have the opportunity to learn from and collaborate with experts in various fields.

Our Founder's story is truly inspiring. He was born and raised in an indigenous community where life was not easy. Growing up, he had to struggle for basic needs such as education and healthcare. Despite the challenges, he was determined to succeed and create a better life for himself and his community.

The lack of basic education in his area didn't deter him from pursuing his dreams. He worked hard and was able to secure various scholarships to continue his education. He had to move to different provinces to get a better education, but he never lost sight of his ultimate goal.

Our Founder's personal experiences motivated him to start Heamac Healthcare, a company focused on maternal and child health. He understood firsthand the unmet needs of his community in this area and was determined to make a difference. He teamed up with highly skilled individuals who shared his vision, and together, they have over a decade of experience in developing medical devices.

Despite the challenges, our Founder's passion and dedication have brought him to where he is today. He has not only created a successful company but has also given back to his community in a meaningful way. His story is a testament to the power of perseverance and the impact one person can have on the world.

At Heamac Healthcare, we have developed a revolutionary solution to address the critical issue of neonatal jaundice, which affects millions of newborn babies worldwide. Our innovative phototherapy device stands out in the market as it addresses the severe jaundice conditions that existing players cannot treat.

Our approach is unique because we have patented our technology to provide the most effective treatment for high-risk jaundice conditions. This sets us apart from the competition, who are only able to address 50% of the market share. With our device, we are able to treat compromised phototherapy cases and prevent critical conditions that could lead to blood transfusion cases.

Our device's modular design and intelligent algorithm make it the only player in the market for critical conditions. Additionally, our device's convertibility feature promotes Home-Phototherapy, making it easier for families to treat their newborns in the comfort of their own homes. This approach is particularly relevant in indigenous communities where access to medical care is limited.

Our solution also overcomes the challenges posed by stringent regulatory policies and the unavailability of new neonatal phototherapy devices, especially in rural areas. We have designed our product to meet regulatory requirements and have tested it for both home care and NICU care.

Our solution has the potential to catalyze positive impacts from others in this space. By providing access to effective phototherapy treatment for high-risk jaundice cases, we can reduce the burden on healthcare systems and prevent critical conditions from developing. This could lead to a reduction in hospital stays and lower healthcare costs, benefiting both patients and healthcare providers.

Overall, we believe that our innovative approach to neonatal phototherapy can change the market significantly. Our solution fills a critical gap in the market and has the potential to revolutionize the way neonatal jaundice is treated. We are excited to showcase our solution at Solve’s 2023 Global Challenges and believe that it has the potential to make a positive impact on the lives of millions of newborns and their families worldwide.

As the founder of Heamac Healthcare, our impact goals for the next year and the next five years are centered around our mission to enhance the lives of the world's Below Poverty Line Population by developing and spreading radically affordable world-class medical products. Specifically, we aim to address the problem of access to and availability of medical care products at a grassroots level, starting with addressing maternal and child health needs, such as the neglected problem of newborn jaundice.

One of our main goals for the next year is to start large-scale manufacturing of our portable phototherapy units and take preorders. Our aim is to sell at least 50 units of the portable version and 100 units of the nLite360 full unit in the incoming year. We will also provide customization for specific needs and requirements. We are actively seeking funding for clinical trials for the nLite360 full-mode version, and we will be requesting support from our investors to achieve this.

In the next five years, our goal is to expand our product line to include other medical devices and solutions that address critical healthcare needs of the Below Poverty Line Population. Our focus will remain on developing user-driven solutions that are affordable and accessible to the most vulnerable communities. We will continue to collaborate with doctors, patients, and other stakeholders to identify the right needs and provide effective solutions.

As a global problem, newborn jaundice affects 70 million babies worldwide. In indigenous communities, this problem is even more severe due to limited access to healthcare and medical resources. Two-thirds of newborns are born with jaundice, and critical jaundice can lead to death or permanent disability if not treated promptly and effectively. This is where our portable phototherapy units come in, as they offer a cost-effective and efficient solution for treating newborn jaundice.

Our clinical trials have demonstrated the effectiveness of our product, and we have received preorders and customer inquiries from more than 25 hospitals for at least 30 units. Each unit has a capability of treating at least 3000 babies over a lifetime of 6 years, making it a highly cost-effective solution. By addressing the problem of newborn jaundice, we hope to contribute to improving maternal and child health outcomes in indigenous communities and other vulnerable populations globally.

In conclusion, at Heamac Healthcare, we are committed to developing and spreading affordable and accessible medical solutions that enhance the lives of the world's Below Poverty Line Population. We will continue to work tirelessly to achieve our impact goals for the next year and the next five years by expanding our product line, collaborating with stakeholders, and addressing critical healthcare needs in indigenous communities and other vulnerable populations globally.

At Heamac Healthcare, we measure our progress toward our impact goals by the number of lives saved through the use of our nLite360 device. As a company, our goal is to enhance the lives of the world's Below Poverty Line Population by developing and spreading radically affordable world-class medical products. Our focus is on addressing maternal and child health needs, where newborn jaundice is one of the most neglected problems globally. With 2/3rd of newborns born with jaundice and critical jaundice leading to death or permanent disability, we understand the severity of this issue and the need for a cost-effective solution.

Our nLite360 device has undergone clinical trials, and we have received pre-orders and inquiries from over 25 hospitals, with a demand for at least 30 products each. Each product has a capability of treating at least 3000 babies in its lifetime of 6 years. By reducing treatment time and cost, our device aims to alleviate the financial burden on families and healthcare facilities, making it accessible to a larger number of people and increasing its reach and impact.

We believe that the impact of our device can be measured by the number of lives saved. The potential to save thousands of lives annually is what drives us to continue working towards our goal. Our device's geographical reach encompasses various regions in India, including rural healthcare centers that lack provisions for treating neonates with jaundice, as well as multispecialty hospitals. The adaptability of our device makes it accessible to both rural and urban healthcare settings, expanding its reach and impact across diverse regions.

We also track our progress by the number of units sold and the number of inquiries and pre-orders received. By selling at least 50 units of the portable version and 100 units of the nLite360 full unit in the incoming year, we will be making progress towards achieving our impact goals. We also provide customization for specific needs and requirements, which is another way of measuring our progress by fulfilling the unique needs of our customers and patients.

In conclusion, measuring our progress towards our impact goals is essential to our company's mission and vision. We believe that the number of lives saved and the number of units sold are both important indicators of our impact. We will continue to focus on developing and spreading affordable medical products to improve the lives of those in need, particularly in indigenous communities where access to healthcare is limited.

Our theory of change is based on the need to solve the critical issue of high-risk jaundice conditions in neonates, which is a global problem affecting many indigenous communities. The current situation where more than 45% of babies receive compromised phototherapy leads to an increased incidence of kernicterus, which causes brain damage and neonatal mortality rates. Our solution, the nLite360 device, is designed to provide an optimum amount of therapy to treat all risk conditions and dynamic conditions, thereby eradicating newborn jaundice conditions.

We believe that our solution will have a significant impact on the problem due to several reasons. Firstly, the device is intelligent, which means it can adjust the treatment to suit the specific condition of the neonate, thereby providing the right amount of therapy. This ensures that the neonate is not under-treated or over-treated, which could result in further complications. Secondly, the device is cost-effective, making it accessible to a larger population, including those from below poverty line families and resource-constrained settings, where the problem is most severe.

To achieve our impact goals, we have a dynamic and diverse team comprising of experts in biodesign, clinical mentors, and educational mentors. We have partnered with various test facilities to conduct regulatory testing to ensure the safety and efficacy of our product. We have also conducted clinical validation from prestigious clinical hospitals in Hyderabad, supported by the Indian Council of Medical Research.

Furthermore, we have received funding support from the Indian government body, BIRAC, DPT, and various other organizations, and have been selected by the ASTMH(American  Society for Tropical Medicine and Health) global competition. We have also presented our product at various healthcare expos in India and on a global platform like Bioasia, Arab Health, and Dubai Expo. Our goal is to provide the best and robust healthcare to these resource-constrained and below poverty areas by entering the homecare market.

In summary, our theory of change is based on the need to solve the critical issue of high-risk jaundice conditions in neonates, which is a global problem affecting many indigenous communities. We believe that our intelligent and cost-effective nLite360 device will have a significant impact on the problem by eradicating newborn jaundice conditions and providing the right amount of therapy to treat all risk conditions and dynamic conditions. Our goal is to provide the best and robust healthcare to these resource-constrained and below poverty areas by entering the homecare market.

We have the advantage of being the monopoly in addressing the severe jaundice condition and also addressing the regular cases with  breastfeeding mode. 

• With this Modular design and the intelligent algorithm which customises the therapy will make us the only player for critical conditions, as well as convertible features promote Home-Phototherapy  as well. 

• A predictive algorithm in neonatology, with initial focus on hyperbilirubinemia, a medical condition affecting half of all new-borns. The  health care professional noncompliance with best practices is the main reason for kernicterus in countries with highest health care standards. Nomogram-based methods are overly general and do not provide an individual prediction of what will happen. Therefore, we aim for personalised prediction by identifying neonates at risk for clinically relevant hyperbilirubinemia more accurately, thus preventing the development of severe neonatal jaundice as well as overtreatment and unnecessary hospital stays.

Our device stands ahead of the competitive devices in the market because of the following unique features:  

1.MULTI SURFACE MODE in Heamac Phototherapy System has 360° coverage of phototherapy light which would address severe jaundice. Currently, 3 devices are pooled together to solve this need. 

2. COMPATIBLE with Neonatal ICU products such as infant incubator, radiant warmer, baby bassinet etc. 

3. Our device provides 3 Times effective therapy compared to traditional/present devices in the market, which reduces 35-50% of the total treatment time. 

s the founder of Heamac Healthcare, I can confidently say that we have conducted extensive testing and validation of our nLite360 device to ensure that it is effective in treating newborn jaundice. We have followed the medical device safety standards and regulations to ensure that our device is safe and effective for use in neonatal phototherapy.

We have conducted electrical safety, mechanical safety, and medical safety tests on our device to ensure that it meets the necessary safety standards. We have also conducted clinical validation studies on our device in collaboration with prestigious clinical hospitals in Hyderabad, India. These studies have shown that our device is effective in treating newborn jaundice and that it is safe for use in neonatal phototherapy.

Furthermore, our device has been designed with the latest technology and artificial intelligence capabilities to ensure that it provides optimum therapy to newborns with jaundice. Our device is also designed to be cost-effective and adaptable to different healthcare settings, making it accessible to a wider population, especially in resource-constrained areas.

We understand that newborn jaundice is a severe problem globally, especially in indigenous communities where access to healthcare and resources is limited. That's why we have designed our device with these communities in mind, ensuring that it is affordable and adaptable to different healthcare settings, including rural healthcare centers that lack provisions for treating neonates with jaundice.

In conclusion, we know that our technology works because we have conducted rigorous testing and validation to ensure its safety and effectiveness. We have also collaborated with prestigious clinical hospitals to conduct clinical validation studies that have shown that our device is effective in treating newborn jaundice. Our device is designed to be adaptable and cost-effective, making it accessible to a wider population, including resource-constrained areas and indigenous communities.

At heamac health care, we believe that strength comes from diverse mindsets. Looking at our founders themselves we have two different diverse co-founders not only concerning gender but race we have diversity even concerning educational skills, qualifications, and backgrounds as well. So our founder itself one of them is prasad mudhham a male founder who is a father having two children and has a very painful experience of them suffering from critical jaundice conditions Our second founder is Akita kolloju who herself has been bought up in a very orthodox and traditional indent family. Where she had struggled a lot to beat the barrier and come out and go for higher studies and also established a company now she is running on her own and also providing employment for many other people. So considering the team and inclusion in our company we take people from various socio-economic backgrounds, and various cultural backgrounds as well, and even in our company also there are 60% female and 40% male and we come from various diverse backgrounds concerning languages, cultural and income levels as well. So we also take this diverse perspective with respect to developing the problem and we always include every team member in order to understand our product ,our vision and also involve them in empathising our customers as well and take diverse perspective ,diverse opinions from different mind sets even during selection criteria we do not have any kind of predefined selection criteria we only have the requirement and if they match the skill set we generally take them and coming to the extra care and extra efforts what we put is that because we come from geogra[hical place where even though fast moving technology and in a 20th generation there are some parents who donot wanted their kids specially women who donot let them do the jobs which they dream and aspire most of them even come to their core job they study different course and end up in software or ant other kind of jobs but we try to understand their passion and give core jobs and equally taken  an extra effort to convience the parents and provide safety and security for women in order to liverage their skill set in the passionate field they diserve to be in. So we have already received a diversity award to maintain this kind of thing.